Ocular Therapeutix (OCUL) Set to Announce Quarterly Earnings on Thursday

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) is set to announce its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.04). The business had revenue of $16.40 million for the quarter, compared to analyst estimates of $15.85 million. Ocular Therapeutix had a negative return on equity of 52.75% and a negative net margin of 226.46%. The business's quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ocular Therapeutix Price Performance

OCUL stock traded down $0.16 during trading on Thursday, hitting $10.78. The company had a trading volume of 825,068 shares, compared to its average volume of 1,884,922. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -8.10 and a beta of 1.26. The company has a current ratio of 16.64, a quick ratio of 16.55 and a debt-to-equity ratio of 0.18. The business has a 50 day moving average of $9.61 and a 200 day moving average of $7.74. Ocular Therapeutix has a fifty-two week low of $2.00 and a fifty-two week high of $11.77.

Wall Street Analyst Weigh In

Several research analysts have issued reports on OCUL shares. Scotiabank assumed coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $14.00 target price on shares of Ocular Therapeutix in a report on Wednesday, October 16th. Finally, Robert W. Baird dropped their price target on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.57.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.